|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | The University of Texas Health Science Center at San Antonio |
|---|---|
| Collaborator: |
American Association of Endodontists |
| Information provided by: | The University of Texas Health Science Center at San Antonio |
| ClinicalTrials.gov Identifier: | NCT00881491 |
Purpose
The purpose of this study is to determine the treatment outcomes in permanent teeth with necrotic pulp and immature root development that undergo a regenerative procedure using a triple antibiotic paste (ciprofloxacin, metronidazole, minocycline) versus a double antibiotic paste (ciprofloxacin, metronidazole)compared to the commonly used mineral trioxide aggregate (MTA) apexification treatment.
| Condition | Intervention | Phase |
|---|---|---|
|
Pulp Necrosis |
Drug: Double Antibiotic Paste Drug: Triple Antibiotic Paste Drug: Mineral Trioxide Aggregate |
Phase 0 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Treatment Outcome With a Revascularization Protocol Using the Triple Versus Double Antibiotic Paste |
| Estimated Enrollment: | 60 |
| Study Start Date: | April 2009 |
| Estimated Study Completion Date: | June 2011 |
| Estimated Primary Completion Date: | June 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Group A
Group A - Double antibiotic paste: intracanal medicament consisting of ciprofloxacin and metronidazole
|
Drug: Double Antibiotic Paste
ciprofloxacin and metronidazole powder mixed at a 1:1 ratio used as a intracanal medicament for disinfection.
|
|
Experimental: Group B
Group B - Triple Antibiotic Paste: intracanal medicament consisting of ciprofloxacin, metronidazole, minocycline
|
Drug: Triple Antibiotic Paste
ciprofloxacin, metronidazole & minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection.
|
|
Active Comparator: Group C
Group C - Mineral trioxide aggregate: used as an apical barrier
|
Drug: Mineral Trioxide Aggregate
standard material providing an apical barrier
|
Recent case series have reported positive outcomes treating necrotic immature permanent teeth with a regenerative procedure using a triple antibiotic paste (ciprofloxacin, metronidazole, minocycline). However, this method can result in considerable staining due to minocycline. In this randomized clinical trial, we will compare clinical outcomes of a triple antibiotic paste versus a double antibiotic paste (ciprofloxacin, metronidazole) intracanal medicament as compared to a standard treatment (immediate apexification with MTA) in permanent teeth with necrotic pulps and immature root development. We hypothesize there will be no significant differences between radiographic measures of root development after treatment with either the double versus triple antibiotic paste, and that both methods will produce significantly greater increases in root length and width compared to standard treatment. The primary outcome measures will be radiographic measurement of root length and dentinal wall thickness and the secondary outcomes will be lack of clinical symptoms and crown staining.
Eligibility| Ages Eligible for Study: | 7 Years to 16 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Erin Locke, RN | 210-567-0895 | locke@uthscsa.edu |
| United States, Texas | |
| University of Texas Health Science Center at San Antonio | Recruiting |
| San Antonio, Texas, United States, 78229 | |
| Contact: Erin Locke, RN 210-567-0895 locke@uthscsa.edu | |
| Principal Investigator: Kenneth M Hargreaves, DDS, PhD | |
| Principal Investigator: | Kenneth M Hargreaves, DDS, PhD | University of Texas |
More Information
| Responsible Party: | Kenneth M. Hargreaves, DDS, PhD, The University of Texas Health Science Center at San Antonio |
| ClinicalTrials.gov Identifier: | NCT00881491 History of Changes |
| Other Study ID Numbers: | HSC20090181H |
| Study First Received: | April 13, 2009 |
| Last Updated: | June 28, 2010 |
| Health Authority: | United States: Food and Drug Administration |
|
Regeneration (revascularization) of dental pulp Immature (not completely developed) permanent tooth with a diagnosis of |
|
Dental Pulp Necrosis Necrosis Dental Pulp Diseases Tooth Diseases Stomatognathic Diseases Pathologic Processes Anti-Bacterial Agents Bacitracin Neomycin Polymyxin B Bacitracin zinc, neomycin sulfate, polymyxin B, drug combination Ciprofloxacin Metronidazole |
Anti-Infective Agents Therapeutic Uses Pharmacologic Actions Nucleic Acid Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Radiation-Sensitizing Agents Physiological Effects of Drugs Antiprotozoal Agents Antiparasitic Agents Anti-Infective Agents, Local Protein Synthesis Inhibitors |